Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global pu...Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global public health. These disorders are associated with multiple insults to the cerebral microcirculation, including reactive oxygen species (ROS) overproduction, leukocyte adhesion and infiltration, brain blood barrier (BBB) disruption, and capillary hypoperfusion, ultimately resulting in tissue edema, hemorrhage, brain injury and delayed neuron damage. Traditional Chinese medicine (TCM) has been used in China, Korea, Japan and other Asian countries for treatment of a wide range of diseases. In China, the usage of compound TCM preparation to treat cerebrovascular diseases dates back to the Han Dynasty. Even thousands of years earlier, the medical formulary recorded many classical prescriptions for treating cerebral I/R-related diseases. This review summarizes current information and underlying mechanisms regarding the ameliorating effects of compound Tem preparation, Chinese materia medica, and active components on I/R-induced cerebral imicrocirculatory disturbances, brain injury and neuron damage. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. Alt rights reserved.展开更多
The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has caused a considerable loss of life,morbidity,and economic distress since its emergence in late 2019.In response to the novel virus,public and...The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has caused a considerable loss of life,morbidity,and economic distress since its emergence in late 2019.In response to the novel virus,public and private institutions around the world have utilized novel technologies to develop a vaccine in the hopes of building herd immunity and ending the pandemic.This review provides an overview of mechanisms and available data on the nascent vaccine technologies undergoing clinical trials to combat SARS-CoV-2,namely,those using protein subunits,viral vectors,mRNA,and DNA.Furthermore,we discuss the potential uses of biomaterials in improving the immunogenicity and safety of these vaccine technologies with the goal of improving upon newly-available technologies to combat future SARS-CoV-2 strains and other emerging viral pathogens.展开更多
Hydrogen sulfide(H_(2)S)has been reported as an endogenous gasotransmitter that contributes to the modulation of a myriad of biological signalling pathways,which includes maintaining homeostasis in living organisms at...Hydrogen sulfide(H_(2)S)has been reported as an endogenous gasotransmitter that contributes to the modulation of a myriad of biological signalling pathways,which includes maintaining homeostasis in living organisms at physiological concentrations,controlling protein sulfhydration and persulfidation for signalling processes,mediating neurodegeneration,and regulating inflammation and innate immunity,etc.As a result,researchers are actively exploring effective approaches to evaluate the properties and the distribution of H_(2)S in vivo.Furthermore,the regulation of the physiological conditions of H_(2)S in vivo introduces the opportunity to further study the molecular mechanisms by which H_(2)S regulates cellular functions.In recent years,many H_(2)S-releasing compounds and biomaterials that can deliver H_(2)S to various body systems have been developed to provide sustained and stable H_(2)S delivery.Additionally,various designs of these H_(2)S-releasing biomaterials have been proposed to aid in the normal conduction of physiological processes,such as cardioprotection and wound healing,by modulating different signalling pathways and cell functionalities.Using biomaterials as a platform to control the delivery of H_(2)S introduces the opportunity to fine tune the physiological concentration of H_(2)S in vivo,a key to many therapeutic applications.In this review,we highlight recent research works concerning the development and application of H_(2)S-releasing biomaterials with a special emphasis to different release triggering conditions in in vivo studies.We believe that the further exploration of the molecular mechanisms underlying H_(2)S donors and their function when incorporated with various biomaterials will potentially help us understand the pathophysiological mechanisms of different diseases and assist the development of H_(2)S-based therapies.展开更多
Perivascular delivery of therapeutic agents against established aetiologies for occlusive vascular remodelling has great therapeutic potential for vein graft failure.However,none of the perivascular drug delivery syst...Perivascular delivery of therapeutic agents against established aetiologies for occlusive vascular remodelling has great therapeutic potential for vein graft failure.However,none of the perivascular drug delivery systems tested experimentally have been translated into clinical practice.In this study,we established a novel strategy to locally and sustainably deliver the cyclin-dependent kinase 8/19 inhibitor Senexin A(SenA),an emerging drug candidate to treat occlusive vascular disease,using graphene oxide-hybridised hyaluronic acid-based hydrogels.We demonstrated an approach to accommodate SenA in hyaluronic acid-based hydrogels through utilising graphene oxide nanosheets allowing for non-covalent interaction with SenA.The resulting hydrogels produced sustained delivery of SenA over 21 days with tunable release kinetics.In vitro assays also demonstrated that the hydrogels were biocompatible.This novel graphene oxide-incorporated hyaluronic acid hydrogel offers an optimistic outlook as a perivascular drug delivery system for treating occlusive vascular diseases,such as vein graft failure.展开更多
文摘Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global public health. These disorders are associated with multiple insults to the cerebral microcirculation, including reactive oxygen species (ROS) overproduction, leukocyte adhesion and infiltration, brain blood barrier (BBB) disruption, and capillary hypoperfusion, ultimately resulting in tissue edema, hemorrhage, brain injury and delayed neuron damage. Traditional Chinese medicine (TCM) has been used in China, Korea, Japan and other Asian countries for treatment of a wide range of diseases. In China, the usage of compound TCM preparation to treat cerebrovascular diseases dates back to the Han Dynasty. Even thousands of years earlier, the medical formulary recorded many classical prescriptions for treating cerebral I/R-related diseases. This review summarizes current information and underlying mechanisms regarding the ameliorating effects of compound Tem preparation, Chinese materia medica, and active components on I/R-induced cerebral imicrocirculatory disturbances, brain injury and neuron damage. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. Alt rights reserved.
文摘The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has caused a considerable loss of life,morbidity,and economic distress since its emergence in late 2019.In response to the novel virus,public and private institutions around the world have utilized novel technologies to develop a vaccine in the hopes of building herd immunity and ending the pandemic.This review provides an overview of mechanisms and available data on the nascent vaccine technologies undergoing clinical trials to combat SARS-CoV-2,namely,those using protein subunits,viral vectors,mRNA,and DNA.Furthermore,we discuss the potential uses of biomaterials in improving the immunogenicity and safety of these vaccine technologies with the goal of improving upon newly-available technologies to combat future SARS-CoV-2 strains and other emerging viral pathogens.
基金This work was partially supported by University of South Carolina and Central South University in China。
文摘Hydrogen sulfide(H_(2)S)has been reported as an endogenous gasotransmitter that contributes to the modulation of a myriad of biological signalling pathways,which includes maintaining homeostasis in living organisms at physiological concentrations,controlling protein sulfhydration and persulfidation for signalling processes,mediating neurodegeneration,and regulating inflammation and innate immunity,etc.As a result,researchers are actively exploring effective approaches to evaluate the properties and the distribution of H_(2)S in vivo.Furthermore,the regulation of the physiological conditions of H_(2)S in vivo introduces the opportunity to further study the molecular mechanisms by which H_(2)S regulates cellular functions.In recent years,many H_(2)S-releasing compounds and biomaterials that can deliver H_(2)S to various body systems have been developed to provide sustained and stable H_(2)S delivery.Additionally,various designs of these H_(2)S-releasing biomaterials have been proposed to aid in the normal conduction of physiological processes,such as cardioprotection and wound healing,by modulating different signalling pathways and cell functionalities.Using biomaterials as a platform to control the delivery of H_(2)S introduces the opportunity to fine tune the physiological concentration of H_(2)S in vivo,a key to many therapeutic applications.In this review,we highlight recent research works concerning the development and application of H_(2)S-releasing biomaterials with a special emphasis to different release triggering conditions in in vivo studies.We believe that the further exploration of the molecular mechanisms underlying H_(2)S donors and their function when incorporated with various biomaterials will potentially help us understand the pathophysiological mechanisms of different diseases and assist the development of H_(2)S-based therapies.
基金The work was supported by United States NIH under the award Nos.R01 GM136877(to QW,JF),R43 HL137525(to TC),R21 EB022131(to TC),P20 GM1090991(to TC),and R01 HL160541(to TC).
文摘Perivascular delivery of therapeutic agents against established aetiologies for occlusive vascular remodelling has great therapeutic potential for vein graft failure.However,none of the perivascular drug delivery systems tested experimentally have been translated into clinical practice.In this study,we established a novel strategy to locally and sustainably deliver the cyclin-dependent kinase 8/19 inhibitor Senexin A(SenA),an emerging drug candidate to treat occlusive vascular disease,using graphene oxide-hybridised hyaluronic acid-based hydrogels.We demonstrated an approach to accommodate SenA in hyaluronic acid-based hydrogels through utilising graphene oxide nanosheets allowing for non-covalent interaction with SenA.The resulting hydrogels produced sustained delivery of SenA over 21 days with tunable release kinetics.In vitro assays also demonstrated that the hydrogels were biocompatible.This novel graphene oxide-incorporated hyaluronic acid hydrogel offers an optimistic outlook as a perivascular drug delivery system for treating occlusive vascular diseases,such as vein graft failure.
